TG Therapeutics (NASDAQ: TGTX) shares have been on a roll since positive data from cancer trials was presented at the annual American Society of Clinical Oncology (ASCO) conference earlier this month. This week, the company’s adding to its good news with updated data for a triplet cancer regimen being presented at the International Conference on Malignant Lymphoma.
Published in TZ Latest News 15 June, 2017 by The TZ Newswire Staff
New Data Shows TG Therapeutics Could Be Onto Something Big
Published in TZ Latest News 15 June, 2017 by The TZ Newswire Staff
New Data Shows TG Therapeutics Could Be Onto Something Big
TG Therapeutics (NASDAQ: TGTX) shares have been on a roll since positive data from cancer trials was presented at the annual American Society of Clinical Oncology (ASCO) conference earlier this month. This week, the company’s adding to its good news with updated data for a triplet cancer regimen being presented at the International Conference on Malignant Lymphoma.